Literature DB >> 21643645

Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients.

Mohamed M Nasrallah1, Amal R El-Shehaby, Noha A Osman, Mona M Salem, Amr Nassef, Usama A A Sharaf El Din.   

Abstract

BACKGROUND: Advanced glycation end-products (AGE) accumulate in CKD and may predispose to cardiovascular disease by inducing inflammatory and oxidant stress in the vascular endothelium. Soluble forms of the receptor for AGE (RAGE) may be protective against these effects by binding AGE in the soluble phase. Accumulating evidence suggests a protective role of soluble RAGE against vascular calcification. This study investigates the association between endogenous soluble RAGE (esRAGE) and vascular calcification in hemodialysis patients.
METHODS: We studied 65 non-diabetic hemodialysis patients, on 3 × 4 h dialysis schedule, and 19 controls. Serum levels of esRAGE, hsCRP, parathormone, lipids, calcium, and phosphorus were measured. Aortic calcification index (ACI) was measured using non-contrast CT of the abdominal aorta.
RESULTS: Aortic calcification was detected in 64 out of 65 hemodialysis patients. Levels of esRAGE were lower in hemodialysis patients (278 pg/ml, SD 101.1) than in controls (443 ± 109 pg/ml; P = 0.001). ACI correlated negatively in stepwise multivariate analysis with esRAGE (P = 0.002) and positively with hsCRP (<0.0001), systolic blood pressure (P < 0.0001) and dialysis vintage (P = 0.05); R (2) = 0.65.
CONCLUSION: Levels of esRAGE were low among hemodialysis patients and correlated negatively with ACI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643645     DOI: 10.1007/s11255-011-0007-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  36 in total

1.  RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.

Authors:  M A Hofmann; S Drury; C Fu; W Qu; A Taguchi; Y Lu; C Avila; N Kambham; A Bierhaus; P Nawroth; M F Neurath; T Slattery; D Beach; J McClary; M Nagashima; J Morser; D Stern; A M Schmidt
Journal:  Cell       Date:  1999-06-25       Impact factor: 41.582

Review 2.  The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.

Authors:  O Hori; S D Yan; S Ogawa; K Kuwabara; M Matsumoto; D Stern; A M Schmidt
Journal:  Nephrol Dial Transplant       Date:  1996       Impact factor: 5.992

Review 3.  Techniques and technologies to assess vascular calcification.

Authors:  Antonio Bellasi; Paolo Raggi
Journal:  Semin Dial       Date:  2007 Mar-Apr       Impact factor: 3.455

Review 4.  Vascular calcifications: pathogenesis, management, and impact on clinical outcomes.

Authors:  Jorge B Cannata-Andía; Minerva Rodríguez-García; Natalia Carrillo-López; Manuel Naves-Díaz; Bernardino Díaz-López
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

5.  Vascular calcification and cardiovascular function in chronic kidney disease.

Authors:  Mhairi Sigrist; Peter Bungay; Maarter W Taal; Christopher W McIntyre
Journal:  Nephrol Dial Transplant       Date:  2005-11-01       Impact factor: 5.992

6.  A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients.

Authors:  Teresa Adragão; Ana Pires; Rita Birne; Jose Dias Curto; Carlos Lucas; Margarida Gonçalves; Acácio Pita Negrão
Journal:  Nephrol Dial Transplant       Date:  2008-10-24       Impact factor: 5.992

7.  Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Authors:  Guillaume Jean; Eric Bresson; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2008-10-13       Impact factor: 5.992

8.  Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Biomark Insights       Date:  2007-09-17

9.  Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease.

Authors:  Giuseppina Basta; Daniela Leonardis; Francesca Mallamaci; Sebastiano Cutrupi; Patrizia Pizzini; Lorena Gaetano; Rocco Tripepi; Giovanni Tripepi; Raffaele De Caterina; Carmine Zoccali
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

Review 10.  Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Biochem Pharmacol       Date:  2010-01-22       Impact factor: 5.858

View more
  9 in total

Review 1.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

2.  Fasting during the month of Ramadan among patients with chronic kidney disease: renal and cardiovascular outcomes.

Authors:  Mohamed M NasrAllah; Noha A Osman
Journal:  Clin Kidney J       Date:  2014-05-31

3.  Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients.

Authors:  Byoung Ho Choi; Han Ro; Eul Sik Jung; Ae Jin Kim; Jae Hyun Chang; Hyun Hee Lee; Wookyung Chung; Ji Yong Jung
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

4.  Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.

Authors:  Abdishakur Abdulle; Claire K Inman; Abdelkarim Saleh; Mohamed Noshi; Divya Galani; Laila Abdelwareth; Habiba Alsafar; Abubaker Elfatih; Hefsa Al Shamsi; Raghib Ali; Huilin Li; Ravichandran Ramasamy; Ann Marie Schmidt; Mahmoud M Benbarka; Mohamed H Hassan
Journal:  J Clin Transl Endocrinol       Date:  2019-04-23

5.  Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.

Authors:  Jenny M Wadén; Emma H Dahlström; Nina Elonen; Lena M Thorn; Johan Wadén; Niina Sandholm; Carol Forsblom; Per-Henrik Groop
Journal:  Diabetologia       Date:  2019-05-24       Impact factor: 10.122

Review 6.  Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models.

Authors:  Lander Egaña-Gorroño; Raquel López-Díez; Gautham Yepuri; Lisa S Ramirez; Sergey Reverdatto; Paul F Gugger; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Front Cardiovasc Med       Date:  2020-03-10

7.  The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers.

Authors:  Mohamed M Nasrallah; Amal R El-Shehaby; Noha A Osman; Tarek Fayad; Amr Nassef; Mona M Salem; Usama A A Sharaf El Din
Journal:  Nephron Extra       Date:  2013-11-06

8.  Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification.

Authors:  Marcelle G A van Eupen; Miranda T Schram; Helen M Colhoun; Jean L J M Scheijen; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  Cardiovasc Diabetol       Date:  2013-10-17       Impact factor: 9.951

9.  Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study.

Authors:  Run Du; Rui Yan Zhang; Lin Lu; Ying Shen; Li Jin Pu; Zheng Bin Zhu; Qi Zhang; Jian Hu; Zhen Kun Yang; Feng Hua Ding; Jian Sheng Zhang; Wei Feng Shen
Journal:  Cardiovasc Diabetol       Date:  2018-11-27       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.